Role of intravitreal brolucizumab with intravitreal rtPA and pneumatic displacement for submacular hemorrhage: A case series

Management of Submacular Hemorrhage Using Intravitreal Brolucizumab with Pneumatic Displacement: A Case Series

“…Bevacizumab (AVASTIN, Genentech, Inc.), ranibizumab (Lucentis®; Genentech, S. San Francisco, CA/Roche, Basel, Switzerland), aflibercept (Eylea®; Regeneron, Tarrytown, NY, USA), and brolucizumab (Beovu®; Novartis, Basel, Switzerland) are the anti-VEGF agents that have been used successfully to treat SMH [ 6 , 7 , 8 ]. Amongst them, there has been a single case series where brolucizumab was administered along with rtPA and C3F8 gas for large SMH secondary to nAMD [ 8 ].…”

“…Bevacizumab (AVASTIN, Genentech, Inc.), ranibizumab (Lucentis®; Genentech, S. San Francisco, CA/Roche, Basel, Switzerland), aflibercept (Eylea®; Regeneron, Tarrytown, NY, USA), and brolucizumab (Beovu®; Novartis, Basel, Switzerland) are the anti-VEGF agents that have been used successfully to treat SMH [ 6 , 7 , 8 ]. Amongst them, there has been a single case series where brolucizumab was administered along with rtPA and C3F8 gas for large SMH secondary to nAMD [ 8 ]. We herein report a novel case series in which patients with large SMH (>4-disc diopters and a thickness of >100 μm on the spectral-domain optical coherence tomography [SD-OCT]) were managed with a combination of intravitreal injection (IVI) of brolucizumab and SF6 gas.…”